Analysts cheered a draft statement from the Centers for Medicare and Medicaid Services (CMS) that said the government plans to pay for prostate cancer treatment Provenge, made by Seattle-based biotechnology firm Dendreon.

FORBES: Provenge's Potential

The stock is also being cheered on by stock analysts and newsletter writers (see box, opposite), who are brushing aside the self-dealing through which Friedland has increased his stake.

FORBES: Magazine Article

The stock is also being cheered on by stock analysts and newsletter writers (see box, p. 132), who are brushing aside the self-dealing through which Friedland has increased his stake.

FORBES: The Promoter